250 related articles for article (PubMed ID: 36344675)
1. Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation.
Stubbs FE; Flynn BP; Rivers CA; Birnie MT; Herman A; Swinstead EE; Baek S; Fang H; Temple J; Carroll JS; Hager GL; Lightman SL; Conway-Campbell BL
Oncogene; 2022 Dec; 41(50):5347-5360. PubMed ID: 36344675
[TBL] [Abstract][Full Text] [Related]
2. SKOV3 cells containing a truncated ARID1a protein have a restricted genome-wide response to glucocorticoids.
Stubbs FE; Birnie MT; Biddie SC; Lightman SL; Conway-Campbell BL
Mol Cell Endocrinol; 2018 Feb; 461():226-235. PubMed ID: 28942102
[TBL] [Abstract][Full Text] [Related]
3. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
4. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
5. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
7. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
Banerjee S; Roy S
Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
[TBL] [Abstract][Full Text] [Related]
8. Targeting ARID1A mutations in cancer.
Mullen J; Kato S; Sicklick JK; Kurzrock R
Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
[TBL] [Abstract][Full Text] [Related]
9. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
[TBL] [Abstract][Full Text] [Related]
10. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
11. The transcriptional histone acetyltransferase cofactor TRRAP associates with the MRN repair complex and plays a role in DNA double-strand break repair.
Robert F; Hardy S; Nagy Z; Baldeyron C; Murr R; Déry U; Masson JY; Papadopoulo D; Herceg Z; Tora L
Mol Cell Biol; 2006 Jan; 26(2):402-12. PubMed ID: 16382133
[TBL] [Abstract][Full Text] [Related]
12. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
13. ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.
Reske JJ; Wilson MR; Armistead B; Harkins S; Perez C; Hrit J; Adams M; Rothbart SB; Missmer SA; Fazleabas AT; Chandler RL
BMC Biol; 2022 Sep; 20(1):209. PubMed ID: 36153585
[TBL] [Abstract][Full Text] [Related]
14. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
15. The Role of the AT-Rich Interaction Domain 1A Gene (
Li JJ; Lee CS
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
[TBL] [Abstract][Full Text] [Related]
16. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Guan B; Wang TL; Shih IeM
Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.
Raab JR; Resnick S; Magnuson T
PLoS Genet; 2015 Dec; 11(12):e1005748. PubMed ID: 26716708
[TBL] [Abstract][Full Text] [Related]
18. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
19. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Yu ZC; Li T; Tully E; Huang P; Chen CN; Oberdoerffer P; Gaillard S; Shih IM; Wang TL
Cancer Res; 2023 Aug; 83(16):2750-2762. PubMed ID: 37306706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
